HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCACAD Consortium

被引:19
作者
Braicu, Elena Ioana [1 ]
Luketina, Hrvoje [1 ]
Richter, Rolf [1 ]
Castillo-Tong, Dan Cacsire [2 ]
Lambrechts, Sandrina [4 ]
Mahner, Sven [5 ]
Concin, Nicole [6 ]
Mentze, Monika [1 ]
Zeillinger, Robert [2 ,3 ]
Vergote, Ignace [4 ]
Sehouli, Jalid [1 ]
机构
[1] Charite, Dept Gynecol, European Competence Ctr Ovarian Canc, D-13353 Berlin, Germany
[2] Med Univ Vienna, Ctr Comprehens Canc, Dept Obstet & Gynecol, Vienna, Austria
[3] Gen Hosp Vienna, Ludwig Boltzmann Cluster Translat Oncol, Vienna, Austria
[4] Katholieke Univ Leuven, Univ Ziekenhuizen Leuven, Dept Obstet & Gynecol, Leuven, Belgium
[5] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol & Gynecol Oncol, Hamburg, Germany
[6] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
来源
ONCOTARGETS AND THERAPY | 2014年 / 7卷
关键词
HIF1; alpha; surgical outcome; platinum response; survival; primary epithelial ovarian cancer; predictive factors; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CLEAR-CELL CARCINOMA; FACTOR; 1-ALPHA; GROWTH-FACTOR; NEOADJUVANT CHEMOTHERAPY; GYNECOLOGICAL CANCER; OVER-EXPRESSION; LUNG-CANCER; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA; OVEREXPRESSION;
D O I
10.2147/OTT.S65373
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Purpose: Hypoxia is a common phenomenon encountered in solid cancers, leading to chemotherapy resistance and therefore to aggressiveness of the disease. The homeostatic response to hypoxia is mediated by hypoxia-inducible factor-1 (HIF-1). The aim of this study was to investigate the impact of HIF1 alpha in patients with primary epithelial ovarian cancer. Methods: In this multicentric study, 275 patients with advanced primary epithelial ovarian cancer were included. All patients underwent cytoreductive surgery with maximal surgical effort and adjuvant platinum-based chemotherapy. HIF1 alpha expression was analyzed in tissue lysates, using an enzyme-linked immunosorbent assay. Results: HIF1 alpha was detected in 79.3% of the tissue samples. Patients with increased HIF1 alpha expression (cutoff: 80 pg/mg protein) in tumoral tissue lysates were more likely to have less favorable survival. HIF1 alpha (P= 0.009, hazard ratio [HR] 2.505, 95% confidence interval [95% CI] 1.252-5.013) together with International Federation of Gynecology and Obstetrics (III versus IV) (P= 0.013, HR 0.540, 95% CI 0.332-0.878), histology (P=0.007, HR 2.748, 95% CI 1.315-5.743), presence of peritoneal carcinomatosis (P=0.014, HR 2.176, 95% CI 1.170-4.046), residual tumor mass (P=0.017, HR 1.641, 95% CI 1.091-2.468), and response to platinum-based chemotherapy (P<0.001, HR 8.131, 95% CI 5.13-12.88) were independent prognosis factors for overall survival. The independent prognostic factors for progression-free survival were International Federation of Gynecology and Obstetrics stage (P=0.01), histological subtypes (P=0.016), and presence of peritoneal carcinomatosis (P<0.05). Conclusion: HIF1 alpha overexpression in ovarian cancer is associated with poor overall survival, underlining the importance of hypoxia in this angiogenesis driven disease.
引用
收藏
页码:1563 / 1569
页数:7
相关论文
共 41 条
[31]   Hypoxia-inducible factor-1α in non small cell lung cancer:: Relation to growth factor, protease and apoptosis pathways [J].
Swinson, DEB ;
Jones, JL ;
Cox, G ;
Richardson, D ;
Harris, AL ;
O'Byrne, KJ .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (01) :43-50
[32]   The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages [J].
Talks, KL ;
Turley, H ;
Gatter, KC ;
Maxwell, PH ;
Pugh, CW ;
Ratcliffe, PJ ;
Harris, AL .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (02) :411-421
[33]   Ethnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan [J].
Tam, KF ;
Chan, YM ;
Ng, TY ;
Wong, LC ;
Ngan, HYS .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) :135-139
[34]  
Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
[35]   Blood Flow and Oxygenation Status of Prostate Cancers [J].
Vaupel, Peter ;
Kelleher, Debra K. .
OXYGEN TRANSPORT TO TISSUE XXXIV, 2013, 765 :299-305
[36]   Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer [J].
Vergote, Ignace ;
Trope, Claes G. ;
Amant, Frederic ;
Kristensen, Gunnar B. ;
Ehlen, Tom ;
Johnson, Nick ;
Verheijen, Rene H. M. ;
van der Burg, Maria E. L. ;
Lacave, Angel J. ;
Panici, Pierluigi Benedetti ;
Kenter, Gemma G. ;
Casado, Antonio ;
Mendiola, Cesar ;
Coens, Corneel ;
Verleye, Leen ;
Stuart, Gavin C. E. ;
Pecorelli, Sergio ;
Reed, Nick S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) :943-953
[37]   Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer [J].
Xiang, Lisha ;
Gilkes, Daniele M. ;
Chaturvedi, Pallavi ;
Luo, Weibo ;
Hu, Hongxia ;
Takano, Naoharu ;
Liang, Houjie ;
Semenza, Gregg L. .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (02) :151-164
[38]   Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes [J].
Yamaguchi, K. ;
Mandai, M. ;
Oura, T. ;
Matsumura, N. ;
Hamanishi, J. ;
Baba, T. ;
Matsui, S. ;
Murphy, S. K. ;
Konishi, I. .
ONCOGENE, 2010, 29 (12) :1741-1752
[39]   Prognostic impact of hypoxia-inducible factors 1α and 2α in colorectal cancer patients:: Correlation with tumor angiogenesis and cyclooxygenase-2 expression [J].
Yoshimura, H ;
Dhar, DK ;
Kohno, H ;
Kubota, H ;
Fujii, T ;
Ueda, S ;
Kinugasa, S ;
Tachibana, M ;
Nagasue, N .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8554-8560
[40]   Expression and significance of TLR4 and HIF-1α in pancreatic ductal adenocarcinoma [J].
Zhang, Jian-Jun ;
Wu, He-Shui ;
Wang, Lin ;
Tian, Yuan ;
Zhang, Jing-Hui ;
Wu, Hai-Long .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (23) :2881-2888